ArticleEClinicalMedicine2024
10-Day versus 14-day bismuth quadruple therapy for first-line eradication of
Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- Trial
- Self-actuated probiotic-nanozyme hybrid system with mucus penetration, biofilm eradication and microbiota regulation for Helicobacter pylori infection.Journal of nanobiotechnology · 2026Article
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- Efficacy of Vonoprazan-Doxycycline Dual Therapy for the Treatment ofInfection and drug resistance · 2026Article
- In silico evaluation of the anti Helicobacter pylori activity of selected bioactive compounds from Aloe vera.Scientific reports · 2025Article
- Silica Spheres Functionalized with Silver and Bismuth Nanoparticles-Antibacterial Activity Against Clinically Relevant Bacterial Pathogens.International journal of molecular sciences · 2025Article
- Comparative Efficacy of Triple Versus Quadruple Therapy for the Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Vonoprazan in Helicobacter pylori treatment regimens in India: Dawn of a New Era.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Review
- Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025Review
- Efficacy and Safety of 10-Day Versus 14-Day Bismuth-Containing Quadruple Therapy forJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Tegoprazan and low- or high-dose amoxicillin dual therapy versus bismuth-containing quadruple therapy forTherapeutic advances in gastroenterology · 2025Article
- Therapeutic advances and future directions inFrontiers in microbiology · 2025Review
- Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy forGastro hep advances · 2025Review
- The oral-gut axis in chronic atrophic gastritis: current perspectives and integrated strategies.Frontiers in immunology · 2025Review
- Concomitant and Bismuth Quadruple Therapy forAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bismuth quadruple therapy is currently consensus recommendation for first-line Methods: For our multicentre, parallel randomised, open-label, and non-inferiority study, we recruited Findings: From August 3, 2020 to April 28, 2023, 313 Interpretation: The 10-day bismuth quadruple therapy was non-inferior to the 14-day therapy as a first-line treatment for eradicating Funding: The National Science and Technology Council and Ministry of Health and Welfare, Taiwan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.